Cancer Research

All Items

• Reply to the letter to the editor by Manzoli, Acuti Martelucci and Flacco (doi: 10.17179/excli2025-9176)

  Marco Alessandria, Franco Berrino, Giovanni M. Malatesta, Alberto Donzelli

  476-478

• Second reply to the second letter to the editor by Alessandria, Berrino, Malatesta and Donzelli (doi: 10.17179/excli2026-9442)

  Lamberto Manzoli, Cecilia Acuti Martellucci, Maria Elena Flacco

  479-480
• 

  Efficacy and safety of CTLA-4, PD-1 and LAG-3 immune checkpoint inhibitors as monotherapy and combination therapy in advanced melanoma: A systematic review and meta-analysis

  Osama Omar Khan

  310-329
• 

  Epigenetic regulation of PANoptosis: DNA methylation, histone modifications and non-coding RNAs

  Yogendra Singh, Muhammad Afzal, M. Arockia Babu, Surya Nath Pandey, Arcot Rekha, Gaurav Gupta, Imran Kazmi, Sami I. Alzarea, Omar Awad Alsaidan, Waleed Hassan Almalki, Salem Salman Almujri

  238-260
• 

  Candesartan cilexetil as a repurposed therapeutic candidate for nasopharyngeal carcinoma: Integrated in vitro and in silico analyses

  Chawalit Ngernsombat, Utid Suriya, Somsiri Udompaisarn, Natta Panomchoeng, Tavan Janvilisri

  204-221

• On the prenatal origins of the myeloproliferative neoplasms

  Stephen E. Langabeer

  189-190
• 

  Methyl linolenate suppresses the growth and proliferation of Ehrlich ascites carcinoma (EAC) cells by inducing intrinsic mitochondrial apoptosis

  Azmin Akter, Tasnima Kamal, M. Matakabbir Hossain, Abdul Auwal, Khan Mohammad Rashel, Tasfik Ul Haque Pronoy, Asmaulhusna Biswas, Sharmin Akter, Mahmud Ismail, M. Rowshanul Habib, Farhadul Islam

  50-67
• 

  IL-8 and follicular fluid: insights into the mechanisms of endometriosis development

  Anne Teresa Heinrich, Ada Leoni Terres-Wurtz, Elisa Vacca, Katrin E. Tagscherer, Bartosz Linek, Susanne Gebhard, Annette Hasenburg, Walburgis Brenner, Roxana Schwab

  1-17

• Reply to the Letter to the editor by Malatesta, Alessandria, Berrino and Donzelli

  Lamberto Manzoli, Cecilia Acuti Martellucci, Maria Elena Flacco

  1800-1801

• Comment to “COVID-19 vaccination, all-cause mortality, and hospitalization for cancer: 30-month cohort study in an Italian province”

  Giovanni M. Malatesta, Marco Alessandria, Franco Berrino, Alberto Donzelli

  1797-1799
• 

  Interplay between hypoxia, RNA methylation, and HPV in head and neck squamous cell carcinomas: drivers of oncogenesis and resistance to therapy

  Marcel Mohr, Julia Kozikowska, Zuzanna Petryszyn, Kamila Ostrowska, Ewelina Golusińska-Kardach, Wojciech Golusiński, Wiktoria Suchorska, Katarzyna Kulcenty

  1767-1796

• Corrigendum "COVID-19 vaccination, all-cause mortality, and hospitalization for cancer: 30-month cohort study in an Italian province"

  Cecilia Acuti Martellucci, Angelo Capodici, Graziella Soldato, Matteo Fiore, Enrico Zauli, Roberto Carota, Marco De Benedictis, Graziano Di Marco, Rossano Di Luzio, Maria Elena Flacco, Lamberto Manzoli

  1740-1742
• 

  Targeting TNFR1-driven necroptosis in breast cancer

  Misbahuddin Rafeeq, Muhammad Afzal, Muhammad Shahid Nadeem, Alaa Hamed Habib, Hadeel A. Alsufyani, Sami I. Alzarea, Omar Awad Alsaidan, Imran Kazmi

  1690-1712

• Antibody-drug conjugates for precision oncology in cholangiocarcinoma

  Parteek Prasher, Mousmee Sharma

  1594-1598
• 

  Recent FDA-approved kinase inhibitors for cancer therapy in 2025: A comprehensive review and perspectives

  Mateen Abbas, Syed Hassam Ali Sami, Márió Gajdács, Muhammad Junaid Tariq

  1609-1633

• An up-to-date review of decursin and its anti-cancer activities

  Chang Ha Park

  1520-1523

• Science in peril: let's fund scientific research in a sustainable and equitable way - a call for international solidarity

  Bachir Benarba, Atanasio Pandiella, Said Hachimi-Idrissi, Francesca Rubulotta, Eddy Lang, Abdelouahab Bellou

  1602-1605

• Comment on “Using novel oxidative phosphorylation inhibitors to attenuate drug resistance in human gliomas” by Tsai et al. (2025)

  Abdullah Saad, Rameen Khan

  1397-1399
• 

  IFN-γ in the tumor microenvironment: dual roles in cancer progression and therapy

  Jiahui Cui, Yi Zhang, Li Yang

  1352-1371
• 

  Berberine pharmacological properties and therapeutic potential across cancer, digestive, metabolic, cardiovascular, and neurological diseases: an update review

  Haoxuan Cheng, Xinyu Li, Yanqi Wang, Wanqing Deng, Guangyong Sun, Dong Zhang, Jianyu Hao, Xinjuan Liu

  1225-1261
• 

  Dual targeting of TIGIT and VISTA in non-small-cell lung cancer immunotherapy

  Alaa A. A. Aljabali, Omar Gammoh, Esam Qnais, Abdelrahim Alqudah, Vijay Mishra, Yachana Mishra, Mohamed El-Tanani

  1100-1142
• 

  Advancing cancer research through 3D cell culture models

  Isidora Panez-Toro, Joshua Mountford, Javier Munoz-Garcia, Dominique Heymann

  1061-1099
• 

  Targeting metabolic vulnerabilities in breast cancer cells by combining PEDF and doxorubicin: pathway insights from GC/MS-based metabolomics

  Raziyeh Abooshahab, Hani Al-Salami, Crispin R. Dass

  1037-1055

• The liver's unexpected ally: on possible liver protection against metastases by hydatid cysts

  Bachir Benarba, Noureddine Bachir Bouiadjra, Atanasio Pandiella

  1023-1026
• 

  Exploring the role of mTOR pathway in aging and age-related disorders

  Komal Raghuvanshi, Disha Raghuvanshi, Dinesh Kumar, Eugenie Nepovimova, Marian Valko, Kamil Kuca, Rachna Verma

  992-1015